Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9932726rdf:typepubmed:Citationlld:pubmed
pubmed-article:9932726lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C0935929lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:9932726lifeskim:mentionsumls-concept:C0675074lld:lifeskim
pubmed-article:9932726pubmed:issue2-3lld:pubmed
pubmed-article:9932726pubmed:dateCreated1999-3-24lld:pubmed
pubmed-article:9932726pubmed:abstractTextJTT-501, 4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxaz olidinedione, is an isoxazolidinedione derivative which is structurally distinct from thiazolidinediones such as pioglitazone and troglitazone. We investigated the effects of JTT-501 on insulin-sensitizing activity and in rodent diabetic models. JTT-501 enhanced insulin-stimulated cell differentiation of 3T3-L1 fibroblasts with an EC50 value of 110 nM. Furthermore, JTT-501 activated peroxisome proliferator-activated (PPA) gamma and alpha receptors with the EC5-fold values of 0.28 and 5.4 microM, respectively. In the non-insulin-dependent diabetes mellitus model KK-Ay mice, JTT-501 improved hyperglycemia, hyperinsulinemia and hypertriglyceridemia, and enhanced insulin-stimulated glucose oxidation in adipose tissues. JTT-501 was also effective in the non-insulin-dependent diabetes mellitus model Zucker diabetic fatty (ZDF) rats but not in the insulin-dependent diabetes mellitus model streptozotocin-induced diabetic mice. These observations suggest that JTT-501 enhances insulin sensitivity in peripheral tissues and improves hyperglycemia, hyperinsulinemia, and hypertriglyceridemia in non-insulin dependent diabetes mellitus models. In particular, the triglyceride-lowering activity of JTT-501 is a unique characteristic compared to the thiazolidinediones. Therefore, JTT-501 may be a promising antidiabetic agent for treating non-insulin-dependent diabetes mellitus patients with insulin resistance.lld:pubmed
pubmed-article:9932726pubmed:languageenglld:pubmed
pubmed-article:9932726pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:citationSubsetIMlld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9932726pubmed:statusMEDLINElld:pubmed
pubmed-article:9932726pubmed:monthJanlld:pubmed
pubmed-article:9932726pubmed:issn0014-2999lld:pubmed
pubmed-article:9932726pubmed:authorpubmed-author:ShibataTTlld:pubmed
pubmed-article:9932726pubmed:authorpubmed-author:ShinkaiHHlld:pubmed
pubmed-article:9932726pubmed:authorpubmed-author:MatsuoAAlld:pubmed
pubmed-article:9932726pubmed:authorpubmed-author:NagaoKKlld:pubmed
pubmed-article:9932726pubmed:authorpubmed-author:WakitaniKKlld:pubmed
pubmed-article:9932726pubmed:authorpubmed-author:YonemoriFFlld:pubmed
pubmed-article:9932726pubmed:issnTypePrintlld:pubmed
pubmed-article:9932726pubmed:day8lld:pubmed
pubmed-article:9932726pubmed:volume364lld:pubmed
pubmed-article:9932726pubmed:ownerNLMlld:pubmed
pubmed-article:9932726pubmed:authorsCompleteYlld:pubmed
pubmed-article:9932726pubmed:pagination211-9lld:pubmed
pubmed-article:9932726pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:meshHeadingpubmed-meshheading:9932726-...lld:pubmed
pubmed-article:9932726pubmed:year1999lld:pubmed
pubmed-article:9932726pubmed:articleTitlePharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.lld:pubmed
pubmed-article:9932726pubmed:affiliationJapan Tobacco, Central Pharmaceutical Research Institute, Takatsuki, Osaka.lld:pubmed
pubmed-article:9932726pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9932726pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9932726lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9932726lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9932726lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9932726lld:pubmed